Since activation of compensatory signalling pathways is a major contributing factor in the development of resistance to kinase inhibitors [26–31], and often goes hand-in-hand with the tumour cell having bypassed the need for the drug target, we therefore investigated whether this was occurring in Eμ-Myc/cRel−/− lymphoma cells. The gene discussed is MYC; the disease is neoplasm.